DAYLI Venture Capital Market Research Report

Background

Company Overview

DAYLI Venture Capital is an early-stage technology investment firm based in Seoul, South Korea. Established in 2016, it operates as the venture capital arm of DAYLI Financial Group, holding a government-licensed venture capital status in the Republic of Korea.

Mission and Vision

DAYLI Venture Capital is dedicated to discovering, building, and investing in next-generation life science companies, focusing on sectors such as bio-healthcare, fintech, and technology. The firm aims to lead industry evolution and innovation through investments grounded in unparalleled expertise and fervent execution.

Primary Area of Focus

The firm's primary focus is on early-stage investments in the bio-healthcare and fintech sectors, targeting companies ranging from early to pre-IPO stages. This includes investments in pharmaceuticals, healthcare, biotechnology, and financial technology.

Industry Significance

As a government-licensed venture capital firm in South Korea, DAYLI Venture Capital plays a pivotal role in fostering innovation and supporting the growth of emerging companies in critical sectors, thereby contributing to the advancement of the nation's economy and technological landscape.

Key Strategic Focus

Core Objectives

• Early-Stage Investment: Focus on identifying and nurturing promising startups in the bio-healthcare and fintech sectors.

• Innovation Leadership: Drive industry evolution by investing in companies that are at the forefront of technological advancements.

• Sustainable Value Creation: Generate long-term value for stakeholders through strategic investments and active portfolio management.

Specific Areas of Specialization

• Bio-Healthcare: Investing in pharmaceuticals, biotechnology, medical devices, and diagnostics.

• Fintech: Supporting innovations in financial technology, including payment systems, digital banking, and financial services.

Key Technologies Utilized

DAYLI Venture Capital leverages its expertise in evaluating and supporting companies that utilize cutting-edge technologies in biotechnology, medical devices, diagnostics, and financial technology.

Primary Markets Targeted

The firm primarily targets the South Korean market, with a strategic focus on companies that have the potential for global expansion.

Financials and Funding

Funding History

Specific details regarding the total funds raised by DAYLI Venture Capital are not publicly disclosed. However, the firm has been actively investing in various sectors, particularly in bio-healthcare and fintech.

Recent Funding Rounds

While exact figures for recent funding rounds are not publicly available, DAYLI Venture Capital has been involved in several significant investments, including:

• BreezeBio: Participated in a Series B - II funding round on February 25, 2026.

• Galux: Invested $29 million on February 9, 2026.

• Orum Therapeutics: Invested $100 million on December 18, 2025.

• Illimis Therapeutics: Invested $42 million on July 14, 2025.

Notable Investors

Specific details about co-investors in these funding rounds are not publicly disclosed.

Utilization of Capital

The capital raised is utilized to support the growth and development of portfolio companies, focusing on scaling operations, advancing research and development, and expanding market reach.

Pipeline Development

Key Pipeline Candidates

DAYLI Venture Capital has invested in several notable companies, including:

• BreezeBio: A biotechnology company specializing in innovative treatments.

• Galux: A firm focused on advancements in medical devices.

• Orum Therapeutics: A company developing cutting-edge therapeutic solutions.

• Illimis Therapeutics: Specializes in novel therapeutic approaches.

Stages of Development

The portfolio companies are at various stages, from early development to pre-IPO, reflecting the firm's strategy of investing across different phases of company growth.

Target Conditions

The investments primarily target conditions in the bio-healthcare sector, including various diseases and medical conditions that can benefit from innovative treatments and technologies.

Anticipated Milestones

Specific timelines for anticipated milestones are not publicly disclosed.

Technological Platform and Innovation

Proprietary Technologies

While specific proprietary technologies are not detailed, DAYLI Venture Capital focuses on companies that develop and utilize innovative technologies in biotechnology, medical devices, diagnostics, and financial technology.

Significant Scientific Methods

The firm supports companies employing advanced scientific methodologies, including cutting-edge research in biotechnology and medical devices.

AI-Driven Capabilities

Specific information regarding AI-driven capabilities within the portfolio companies is not publicly available.

Leadership Team

Key Executives

• Seung-Ho Lee: Chief Executive Officer. Details about his professional background and contributions are not publicly disclosed.

• In-Ho Kwon: Managing Director. Professional background details are not publicly disclosed.

• Eun-Seok Lee: Managing Director. Professional background details are not publicly disclosed.

Leadership Changes

Specific details regarding recent leadership changes or appointments are not publicly available.

Competitor Profile

Market Insights and Dynamics

The venture capital market in South Korea is dynamic, with a growing emphasis on bio-healthcare and fintech sectors. The government's support for innovation and entrepreneurship contributes to a favorable environment for venture capital activities.

Competitor Analysis

DAYLI Venture Capital operates in a competitive landscape with several other venture capital firms focusing on similar sectors. Notable competitors include:

• Kleiner Perkins